We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTILS
RNS Number : 9853N
Tiziana Life Sciences PLC
05 October 2021
PDMR Dealing
London, New York, 5 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 60,000 ordinary shares of 3p each in the market at a price of 50p per share.
The acquisition takes Mr Cerrone's interests from 34.148% to 34.178% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).
1. Details of PDMR / person closely associated a) Name Gabriele Cerrone ------------------ ------------------------------------------------- 2. Reason for the notification --------------------------------------------------------------------- a) Position Chairman / status ------------------ ------------------------------------------------- b) Initial Initial notification notification /amendment ------------------ ------------------------------------------------- 3. Details of the issuer --------------------------------------------------------------------- a) Name Tiziana Life Sciences plc ------------------ ------------------------------------------------- b) LEI 213800CED47HI8PIOB36 ------------------ ------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------- a) Description Ordinary Shares of 3p each of the financial instrument ------------------ ------------------------------------------------- b) Identification ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 code of the Financial Instrument ------------------ ------------------------------------------------- c) Nature Market Purchase of the transaction ------------------ ------------------------------------------------- Price(s) 50p d) and volume(s) 60,000 ------------------ ------------------------------------------------- f) Date of 4 October 2021 the transaction ------------------ ------------------------------------------------- g) Place of XLON the transaction ------------------ -------------------------------------------------
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
For further enquiries:
Tiziana Life Sciences plc +44 (0)20 7495 2379 Gabriele Cerrone, Chairman, and founder United States: Investors: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUSRORAOURRUA
(END) Dow Jones Newswires
October 05, 2021 02:00 ET (06:00 GMT)
1 Year Tiziana Life Sciences Chart |
1 Month Tiziana Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions